An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

NCT01458236 ·Status: WITHDRAWN ·Phase: PHASE3

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

NCT02759419 ·Status: COMPLETED ·Phase: PHASE4

Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension

NCT01847716 ·Status: TERMINATED

Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE

NCT01827059 ·Status: UNKNOWN ·Phase: PHASE2

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

NCT00863681 ·Status: COMPLETED ·Phase: PHASE3

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

NCT05764265 ·Status: TERMINATED ·Phase: PHASE2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820 ·Status: RECRUITING ·Phase: PHASE2

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

NCT03556020 ·Status: TERMINATED ·Phase: PHASE2

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916 ·Status: WITHDRAWN ·Phase: PHASE3

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

NCT03315507 ·Status: COMPLETED ·Phase: PHASE1

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428 ·Status: TERMINATED ·Phase: PHASE2

Apabetalone for Pulmonary Arterial Hypertension

NCT04915300 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00810693 ·Status: COMPLETED ·Phase: PHASE3

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

NCT03602781 ·Status: WITHDRAWN ·Phase: PHASE3

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

NCT02939599 ·Status: TERMINATED ·Phase: PHASE2

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372 ·Status: TERMINATED ·Phase: PHASE3

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

NCT04955990 ·Status: TERMINATED ·Phase: PHASE4

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

NCT03068130 ·Status: TERMINATED ·Phase: PHASE3

Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

NCT03655704 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Inhaled Treprostinil for PAH: Open-label Extension

NCT01557660 ·Status: WITHDRAWN ·Phase: PHASE3

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

NCT02279160 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

NCT00887978 ·Status: COMPLETED ·Phase: PHASE3

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

NCT00091715 ·Status: COMPLETED ·Phase: PHASE3